[go: up one dir, main page]

PE20091337A1 - Cristalizacion de anticuerpos anti-cd20 - Google Patents

Cristalizacion de anticuerpos anti-cd20

Info

Publication number
PE20091337A1
PE20091337A1 PE2008002155A PE2008002155A PE20091337A1 PE 20091337 A1 PE20091337 A1 PE 20091337A1 PE 2008002155 A PE2008002155 A PE 2008002155A PE 2008002155 A PE2008002155 A PE 2008002155A PE 20091337 A1 PE20091337 A1 PE 20091337A1
Authority
PE
Peru
Prior art keywords
antibody
hccf
concentrate
solution
cell culture
Prior art date
Application number
PE2008002155A
Other languages
English (en)
Inventor
James A Wilkins
Shadia Abike Oshodi
Brian Lobo
Timothy N Breece
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20091337A1 publication Critical patent/PE20091337A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

REFERIDA UN PROCEDIMIENTO PARA PURIFICAR UN ANTICUERPO CD20 TAL COMO UN ANTICUERPO 2H7 CD20 DE VARIANTES A-I, DE UNA MEZCLA QUE ES UN FLUIDO DE CULTIVO CELULAR CONCENTRADO COSECHADO (HCCF) DE UN CULTIVO CELULAR RECOMBINANTE DE CELULAS MAMIFERAS DE OVARIO DE HAMSTER CHINO, DONDE DICHO PROCEDIMIENTO COMPRENDE: a) CONCENTRAR EL HCCF A UNA CONCENTRACION DE 1.5 mg/Ml, b) CRISTALIZAR EL ANTICUERPO CD20 A UN pH DE 7.8 ± 0.2 Y A UNA TEMPERATURA DE ENTRE 4ºC Y 40ºC, c) DISOLVER LOS CRISTALES CD20 PARA OBTENER UNA SOLUCION CD20, d) SOMETER DICHA SOLUCION A PURIFICACION EN UNA COMLUMNA DE INTERCAMBIO DE ANIONES, Y e) AISLAR EL ANTICUERPO CD20
PE2008002155A 2007-12-21 2008-12-19 Cristalizacion de anticuerpos anti-cd20 PE20091337A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1628807P 2007-12-21 2007-12-21

Publications (1)

Publication Number Publication Date
PE20091337A1 true PE20091337A1 (es) 2009-09-03

Family

ID=40347971

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002155A PE20091337A1 (es) 2007-12-21 2008-12-19 Cristalizacion de anticuerpos anti-cd20

Country Status (15)

Country Link
US (1) US20110020322A1 (es)
EP (1) EP2235056A1 (es)
JP (1) JP2011507870A (es)
KR (1) KR20100105720A (es)
CN (1) CN101945890A (es)
AR (1) AR069860A1 (es)
AU (1) AU2008343347A1 (es)
BR (1) BRPI0820604A2 (es)
CA (1) CA2708951A1 (es)
CL (1) CL2008003790A1 (es)
IL (1) IL206227A0 (es)
PE (1) PE20091337A1 (es)
RU (1) RU2010130467A (es)
TW (1) TW200932758A (es)
WO (1) WO2009085765A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2708095T3 (es) 2003-11-05 2019-04-08 Roche Glycart Ag Anticuerpos de CD20 con afinidad de unión a receptor de Fc y función efectora incrementadas
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
CN101577344B (zh) * 2009-06-11 2011-04-20 珠海银通交通能源投资有限公司 动力电池
CN102712691A (zh) 2009-08-06 2012-10-03 弗·哈夫曼-拉罗切有限公司 蛋白质纯化中提高病毒去除的方法
US20150133642A1 (en) * 2012-05-11 2015-05-14 Dariusch Hekmat Crystallization methods for purification of monoclonal antibodies
LT2864346T (lt) * 2012-06-21 2019-01-25 Synthon Biopharmaceuticals B.V. Antikūnų gryninimo metodas
US10293106B2 (en) 2013-04-03 2019-05-21 Becton, Dickinson And Company Intravenous tubing set modified for in-line catheter flushing
KR101569783B1 (ko) * 2013-06-05 2015-11-19 한화케미칼 주식회사 항체의 정제 방법
KR20220116581A (ko) 2013-12-17 2022-08-23 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
WO2016040868A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
US20180164221A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019157308A1 (en) 2018-02-08 2019-08-15 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2022098628A2 (en) 2020-11-04 2022-05-12 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
AU2021374592A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
EP4240493A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
IT202100004496A1 (it) 2021-02-25 2022-08-25 Univ Della Calabria Recupero di farmaci biologici o loro frammenti da soluzioni impure mediante cristallizzazione o precipitazione con membrane
IL308417A (en) 2021-05-14 2024-01-01 Genentech Inc Methods for the treatment of CD20-positive proliferative disorder with musuntozumab and folatuzumab and dotin
CA3236006A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5509070A (en) * 1992-12-15 1996-04-16 Softlock Services Inc. Method for encouraging purchase of executable and non-executable software
US6134659A (en) * 1998-01-07 2000-10-17 Sprong; Katherine A. Controlled usage software
KR20030074693A (ko) * 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)

Also Published As

Publication number Publication date
AU2008343347A1 (en) 2009-07-09
TW200932758A (en) 2009-08-01
JP2011507870A (ja) 2011-03-10
IL206227A0 (en) 2010-12-30
KR20100105720A (ko) 2010-09-29
CL2008003790A1 (es) 2010-02-05
EP2235056A1 (en) 2010-10-06
WO2009085765A1 (en) 2009-07-09
US20110020322A1 (en) 2011-01-27
RU2010130467A (ru) 2012-01-27
CA2708951A1 (en) 2009-07-09
BRPI0820604A2 (pt) 2017-05-09
AR069860A1 (es) 2010-02-24
CN101945890A (zh) 2011-01-12

Similar Documents

Publication Publication Date Title
PE20091337A1 (es) Cristalizacion de anticuerpos anti-cd20
PE20081258A1 (es) ANTICUERPOS ANTI-hTNFALFA CRISTALINOS
AR121861A2 (es) MÉTODO PARA PREPARAR UNA COMPOSICIÓN DE IgG ENRIQUECIDA A PARTIR DE PLASMA
Porotto et al. Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry
NZ580379A (en) Crystalline anti-human il-12 antibodies
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
ECSP12012026A (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
BRPI1016156B8 (pt) Composições de glifosato e de sais de 2,4-d com alto poder herbicida, e método para controle de vegetações indesejáveis em plantações
BR112014032567A2 (pt) purificação de iduronato-2-sulfatase
BR112014005064A2 (pt) não solvatos de sal de norigobaína
AR086525A1 (es) Metodo de purificacion de anticuerpos
BR112013002125A2 (pt) derivados de c-aril glicosídeo, seus usos e seu processo de preparação, bem como composição farmacêutica
AR071236A1 (es) Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
BRPI0820749B8 (pt) derivados de peptídeo mimético de eritropoietina e seu sal farmaceuticamente aceitável, método para preparação dos referidos derivados, composição farmacêutica e usos dos mesmos
CO6241165A2 (es) Uso de temperatura baja y/o ph bajo en el cultivo de celulas
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
AR086198A1 (es) Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen
NI201000234A (es) Una nueva sal de glicinato de metformina para el control de la glucosa en sangre.
AR074894A1 (es) Procedimiento para purificar un alcohol a partir de un caldo de fermentacion usando un evaporador de pelicula descendente , de pelicula agitada o de corto recorrido
DOP2012000239A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
AR078627A1 (es) N-((1r,2s,5r)-5-terc-butilamino)-2-((s)-3-(7-terc-butilpirazolo[1,5-a][1,3,5]triazin-4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, forma cristalina, procedimiento de preparacion, composiciones farmaceuticas que los comprenden y uso del mismo para tratar diabetes, obesidad, enfermedades alerg
BR112013028679A2 (pt) inibidores do vírus da hepatite c
CL2010001070A1 (es) Mezclas herbicidas sinérgicas que comprende picolinafen y un segundo compuesto selecto entre cuatro subgrupos de sulfonilureas y opcionalmente un antídoto;composición que comprende dicha mezcla herbicida junto a un soporte liquido y/o sólido y método que las emplea para combatir vegetación no deseada .solic.div .de 522-2004
EA200601562A1 (ru) Сокристаллы госсипола и их применение
BR112014000522A2 (pt) meio de cultura, método para cultivar salmonella e e. coli e método para detectar salmonella e e. coli

Legal Events

Date Code Title Description
FD Application declared void or lapsed